Edwards Lifesciences Corporation
- Jurisdiction
United States - LEI
YA13X31F3V31L8TMPR58 - ISIN
US28176E1082 (EW )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Read full profile
Fundamentals
- Net revenue
€4.85B - Gross margin
78.9% - EBIT
€1.32B - EBIT margin
27.2% - Net income
€3.54B - Net margin
73.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Chopra Daveen | CVP, TMTT |
|
|
|
|
| Wood Larry L | Global President TAVR & Surg |
|
|
|
|
| Lippis Daniel J. | CVP, JAPAC |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Jefferson Shreve | June 22, 2025 | $50.00K–$100.00K |
| Bruce Westerman | May 12, 2025 | $1.00K–$15.00K |
| Robert Bresnahan | May 8, 2025 | $1.00K–$15.00K |
| Jefferson Shreve | May 8, 2025 | $15.00K–$50.00K |
| Bruce Westerman | April 16, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
| James Anderson |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Sell |